Your email has been successfully added to our mailing list.

×
0.0363636363636365 0.00606060606060615 0 0.0593939393939394 0.198787878787879 0.210909090909091 0.173333333333333 0.652121212121212
Stock impact report

Cyclacel up 38% premarket on COVID-19 plan in UK [Seeking Alpha]

Cyclacel Pharmaceuticals, Inc. (CYCC) 
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations
Company Research Source: Seeking Alpha
Cyclacel Pharmaceuticals (NASDAQ:CYCCenteredThe parties will assess Cyclacel’s medicines above for their suitability for use in safety and efficacy studies in COVID-19 patients. This evaluation is part of a broader project (“STOPCOVID”) studying the inflammatory pathways that lead directly to COVID-19 lung injury.Shares are up38% Show less Read more
Impact Snapshot
Event Time:
CYCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CYCC alerts
Opt-in for
CYCC alerts

from News Quantified
Opt-in for
CYCC alerts

from News Quantified